Free Trial
LON:HVO

hVIVO (HVO) Share Price, News & Analysis

hVIVO logo
GBX 28.30
-0.20 (-0.70%)
(As of 11/1/2024 ET)

About hVIVO Stock (LON:HVO)

Key Stats

Today's Range
28
28.92
50-Day Range
26
29.80
52-Week Range
16.76
32
Volume
3.76 million shs
Average Volume
3.44 million shs
Market Capitalization
£192.54 million
P/E Ratio
943.33
Dividend Yield
0.73%
Price Target
N/A
Consensus Rating
N/A

Company Overview

hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

The Group's fast-growing services business includes a unique portfolio of 10+ human challenge models to test a broad range of infectious and respiratory disease products, world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.

hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester.

Receive HVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for hVIVO and its competitors with MarketBeat's FREE daily newsletter.

HVO Stock News Headlines

hVIVO plc (HVO.IR)
We recommended Nvidia in 2016, now we’re recommending this…
The AI boom is just getting started. And the real wealth has still to be made…
hVIVO Share Chat (HVO)
See More Headlines

HVO Stock Analysis - Frequently Asked Questions

hVIVO's stock was trading at GBX 23.75 on January 1st, 2024. Since then, HVO stock has increased by 19.2% and is now trading at GBX 28.30.
View the best growth stocks for 2024 here
.

hVIVO plc (LON:HVO) announced its quarterly earnings data on Thursday, April, 19th. The company reported ($16.50) EPS for the quarter, missing analysts' consensus estimates of ($10.90) by $5.60. hVIVO had a net margin of 25.96% and a trailing twelve-month return on equity of 58.04%.

Shares of HVO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that hVIVO investors own include ValiRx (VAL), boohoo group (BOO), Petrofac (PFC), Lloyds Banking Group (LLOY), Falanx Group (FLX), IQE (IQE) and Rolls-Royce Holdings plc (RR).

Company Calendar

Last Earnings
4/19/2018
Today
11/02/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
£17.45 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£67.21 million
Cash Flow
GBX 5.73 per share
Book Value
GBX 6 per share

Miscellaneous

Free Float
N/A
Market Cap
£192.54 million
Optionable
Not Optionable
Beta
0.97
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

This page (LON:HVO) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners